RAPT Therapeutics (NASDAQ:RAPT) CEO Brian Russell Wong Buys 2,000 Shares

RAPT Therapeutics (NASDAQ:RAPT) CEO Brian Russell Wong purchased 2,000 shares of the stock in a transaction dated Wednesday, September 23rd. The shares were acquired at an average cost of $30.06 per share, for a total transaction of $60,120.00.

Shares of RAPT traded down $5.11 during trading hours on Wednesday, hitting $28.61. 610,152 shares of the company were exchanged, compared to its average volume of 143,839. The firm has a fifty day simple moving average of $28.82 and a 200-day simple moving average of $22.42. The company has a market capitalization of $700.06 million and a PE ratio of -1.99. RAPT Therapeutics has a one year low of $10.52 and a one year high of $51.21.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.51) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.07. The company had revenue of $1.28 million during the quarter, compared to analyst estimates of $2.50 million. Equities analysts anticipate that RAPT Therapeutics will post -2.12 earnings per share for the current fiscal year.

RAPT has been the subject of several research analyst reports. HC Wainwright upped their price objective on shares of RAPT Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 14th. BMO Capital Markets raised their price objective on shares of RAPT Therapeutics from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Zacks Investment Research lowered RAPT Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 15th. BidaskClub upgraded RAPT Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, September 7th. Finally, Wells Fargo & Company upped their price objective on RAPT Therapeutics from $33.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, July 13th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $39.86.

Several institutional investors and hedge funds have recently made changes to their positions in RAPT. Ameritas Investment Partners Inc. increased its position in shares of RAPT Therapeutics by 617.8% in the second quarter. Ameritas Investment Partners Inc. now owns 969 shares of the company’s stock worth $28,000 after acquiring an additional 834 shares in the last quarter. First Mercantile Trust Co. acquired a new position in RAPT Therapeutics in the 2nd quarter worth approximately $93,000. Wells Fargo & Company MN grew its position in RAPT Therapeutics by 38.5% during the 1st quarter. Wells Fargo & Company MN now owns 13,363 shares of the company’s stock worth $284,000 after purchasing an additional 3,712 shares in the last quarter. Parallel Advisors LLC acquired a new stake in RAPT Therapeutics during the 2nd quarter valued at $129,000. Finally, American International Group Inc. raised its stake in RAPT Therapeutics by 537.8% during the 2nd quarter. American International Group Inc. now owns 6,710 shares of the company’s stock valued at $195,000 after purchasing an additional 5,658 shares during the period. Institutional investors own 58.04% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases.

Featured Article: Buy Rating

Insider Buying and Selling by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit